Pulmatrix PE Ratio 2014-2021 | PULM
For a detailed definition, formula and example for PE Ratio, check out our new background page here.
Current and historical p/e ratio for Pulmatrix (PULM) from 2014 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Pulmatrix PE ratio as of October 26, 2021 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Pulmatrix PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2021-10-27 |
0.78 |
|
0.00 |
| 2021-06-30 |
1.04 |
$-0.52 |
0.00 |
| 2021-03-31 |
1.33 |
$-0.50 |
0.00 |
| 2020-12-31 |
1.19 |
$-0.64 |
0.00 |
| 2020-09-30 |
1.19 |
$-0.76 |
0.00 |
| 2020-06-30 |
1.72 |
$-0.63 |
0.00 |
| 2020-03-31 |
1.01 |
$-0.99 |
0.00 |
| 2019-12-31 |
0.86 |
$-1.50 |
0.00 |
| 2019-09-30 |
0.82 |
$-1.33 |
0.00 |
| 2019-06-30 |
0.92 |
$-2.15 |
0.00 |
| 2019-03-31 |
1.27 |
$-3.04 |
0.00 |
| 2018-12-31 |
2.40 |
$-4.70 |
0.00 |
| 2018-09-30 |
3.70 |
$-4.70 |
0.00 |
| 2018-06-30 |
4.50 |
$-5.90 |
0.00 |
| 2018-03-31 |
5.09 |
$-7.50 |
0.00 |
| 2017-12-31 |
14.10 |
$-7.20 |
0.00 |
| 2017-09-30 |
20.50 |
$-7.20 |
0.00 |
| 2017-06-30 |
23.80 |
$-7.10 |
0.00 |
| 2017-03-31 |
34.90 |
$-10.40 |
0.00 |
| 2016-12-31 |
5.90 |
$-12.10 |
0.00 |
| 2016-09-30 |
16.50 |
$-16.70 |
0.00 |
| 2016-06-30 |
19.60 |
$-18.00 |
0.00 |
| 2016-03-31 |
29.30 |
$-38.40 |
0.00 |
| 2015-12-31 |
42.00 |
$-34.60 |
0.00 |
| 2015-09-30 |
49.10 |
$-47.25 |
0.00 |
| 2015-06-30 |
96.00 |
$-52.60 |
0.00 |
| 2015-03-31 |
86.00 |
$-35.00 |
0.00 |
| 2014-12-31 |
87.50 |
$-46.50 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.040B |
$0.013B |
|
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.
|
